Last 3,646
Change Today 0.00 / 0.00%
Volume 0.0
EVGN On Other Exchanges
Symbol
Exchange
New York
Tel Aviv
As of 10:24 AM 11/27/14 All times are local (Market data is delayed by at least 15 minutes).

evogene ltd (EVGN) Snapshot

Open
$3,414
Previous Close
$3,412
Day High
$3,682
Day Low
$3,414
52 Week High
01/1/14 - $6,995
52 Week Low
11/26/14 - $3,400
Market Cap
923.5M
Average Volume 10 Days
29.2K
EPS TTM
$-0.59
Shares Outstanding
25.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EVOGENE LTD (EVGN)

Related News

No related news articles were found.

evogene ltd (EVGN) Related Businessweek News

No Related Businessweek News Found

evogene ltd (EVGN) Details

Evogene Ltd. operates as a plant genomics company that uses a technology infrastructure to enhance seed traits underlying crop productivity. The company operates in two segments, Evogene and Evofuel. The Evogene segment develops technologies to enhance plant performance through seed traits and ag-chemicals. Its seed trait operation utilizes to address yield and abiotic stress and biotic stress traits through the genetic modification or breeding of seeds; and ag-chemical operations utilize to develop novel crop protection and crop enhancement products, including herbicides. The Evofuel segment develops species of the castor bean plant for second generation feedstock for use in the alternative fuel industry, specifically biodiesel and biojet. Its products focus on various crops comprising corn, soybean, wheat, rice, and cotton. Evogene Ltd. has strategic collaborations with agricultural companies primarily to develop traits for yield and abiotic stress tolerance, such as enhanced tolerance to drought, heat, and salinity; and biotic stress resistance, including resistance to disease, pests, and insects. The company was founded in 1999 and is headquartered in Rehovot, Israel.

192 Employees
Last Reported Date: 04/8/14
Founded in 1999

evogene ltd (EVGN) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $749.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $352.0K
Chief Technology Officer and Executive Vice P...
Total Annual Compensation: $304.0K
Executive Vice President of Technology Infras...
Total Annual Compensation: $303.0K
Executive Vice President of Strategy and Busi...
Total Annual Compensation: $406.0K
Compensation as of Fiscal Year 2013.

evogene ltd (EVGN) Key Developments

Evogene Ltd. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Evogene Ltd. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company recorded total revenues were $3,164,000 compared to $4,234,000 for the same period a year ago. Operating loss was $4,306,000 compared to $2,528,000 for the same period a year ago. Net loss and comprehensive loss was $4,179,000 or $0.17 per basic and diluted share compared to $2,299,000 or $0.12 per basic and diluted share for the same period a year ago. Net cash used in operating activities was $2,042,000 compared to $1,470,000 for the same period a year ago. Purchase of property, plant and equipment was $1,387,000 compared to $605,000 for the same period a year ago. The decline in Revenue was primarily related to the amendment to the company's Bayer collaboration work plan, whereby $750,000 of research payments due in 2014 were accounted for as deferred revenues and will be recognized as revenues in 2015 and onwards. This decline was offset in part by an increase in revenues associated with the expansion of activities in certain other collaborations, including the company's agreements with Monsanto and Syngenta, which were extended and expanded in late 2013. Operating loss increase was mainly attributable to the increase in self-funded research and development expenses, among other operating expenses and non-cash share-based compensation expenses, as described above. For the nine months, the company reported total revenues were $10,871,000 compared to $13,168,000 for the same period a year ago. Operating loss was $10,659,000 compared to $4,677,000 for the same period a year ago. Net loss and comprehensive loss was $9,707,000 or $0.39 per basic and diluted share compared to $4,661,000 or $0.25 per basic and diluted share for the same period a year ago. Net cash used in operating activities was $7,313,000 compared to $4,772,000 for the same period a year ago. Purchase of property, plant and equipment was $2,312,000 compared to $1,336,000 for the same period a year ago.

Evogene Ltd. Opens Dedicated R&D Facilities at its Rehovot Facility

Evogene Ltd. has opened dedicated R&D facilities at its Rehovot facility to support the company's product programs focusing on fungus, insect and weed control. Evogene strives to improve crop productivity and economics for the food, feed and biofuel industries. The newly completed facilities support these new and increased areas of activity, and are part of Evogene's $10 million investment in expanding its existing knowledge base, computational platforms, and testing and validation capabilities.

Evogene Ltd. to Report Q3, 2014 Results on Nov 10, 2014

Evogene Ltd. announced that they will report Q3, 2014 results at 2:00 PM, GMT Standard Time on Nov 10, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EVGN:IT 3,646.00 0.00

EVGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EVGN.
View Industry Companies
 

Industry Analysis

EVGN

Industry Average

Valuation EVGN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EVOGENE LTD, please visit www.evogene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.